Cerebrospinal fluid MTBR243 tau correlates with [18F] GTP1 Tau PET and the two biomarkers show similar correlations with clinical measures
Guardado en:
| Publicado en: | Alzheimer's & Dementia vol. 21 (Dec 1, 2025) |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , , , , , , , , , |
| Publicado: |
John Wiley & Sons, Inc.
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3286011805 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1552-5260 | ||
| 022 | |a 1552-5279 | ||
| 024 | 7 | |a 10.1002/alz70861_108306 |2 doi | |
| 035 | |a 3286011805 | ||
| 045 | 0 | |b d20251201 | |
| 100 | 1 | |a Verghese, Philip B. |u C2N Diagnostics LLC, St. Louis, MO, USA | |
| 245 | 1 | |a Cerebrospinal fluid MTBR243 tau correlates with [18F] GTP1 Tau PET and the two biomarkers show similar correlations with clinical measures | |
| 260 | |b John Wiley & Sons, Inc. |c Dec 1, 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background Tau tangle neuropathology can be visualized in living individuals using radioligands that bind specifically to aggregated tau. MTBR243 is a biomarker that has been found to be strongly associated with the presence of tau tangles in the brain. In this analysis we compared MTBR243 measured in CSF to Tau PET and clinical variables. Method MTBR243 was analyzed in 200 baseline CSF samples from study participants from two clinical trials in early and mild‐to‐moderate Alzheimer’s Disease (AD) (Tauriel, NCT03289143 and Lauriet, NCT03828747), including 182 participants who also had Tau PET data using [18F]GTP1 tau PET tracer. All subjects were amyloid positive per study inclusion criteria. Tau PET results were analyzed as continuous variable using the Temporal Meta ROI SUVR and dichotomized as low/high based on Temporal Meta ROI SUVR of 1.33. Clinical measures at baseline included CDR‐SB, ADAS‐Cog11, ADCS‐ADL, and MMSE. Result The CSF MTBR243 concentration had high correlation with Tau PET SUVR (Spearman’s ρ = 0.69, 95% CI 0.60‐0.76). 69.8% were classified as high Tau PET in the participants who were analyzed for MTBR243 in CSF. The AUC‐ROC of CSF MTBR243 for identifying Tau PET positivity was 0.89 (95% CI: 0.84‐0.94). We found that both Tau PET and CSF MTBR243 correlated with all 4 clinical measures at baseline as well as change from baseline. The correlations for the two biomarkers with clinical measures were very similar. Conclusion CSF MTBR243 correlates well with Tau PET in this amyloid positive population and discriminates well between low and high Tau PET patients. Tau PET and CSF MTBR243 have similar correlations to clinical variables, suggesting that CSF MTBR243 could be a suitable candidate as a fluid surrogate biomarker for Tau PET. | |
| 653 | |a Variables | ||
| 653 | |a Cerebrospinal fluid | ||
| 653 | |a Clinical trials | ||
| 653 | |a Brain | ||
| 653 | |a Biological markers | ||
| 653 | |a Time | ||
| 653 | |a Clinical research | ||
| 653 | |a Activities of daily living | ||
| 653 | |a Biomarkers | ||
| 653 | |a Patients | ||
| 653 | |a Neuropathology | ||
| 653 | |a Mini-Mental State Examination | ||
| 653 | |a Candidates | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a Clinical variables | ||
| 700 | 1 | |a Meyer, Matthew R. |u C2N Diagnostics, LLC, Saint Louis, MO, USA | |
| 700 | 1 | |a Tzeng, Shin‐Cheng |u C2N Diagnostics, LLC, Saint Louis, MO, USA | |
| 700 | 1 | |a Rabe, Christina |u Genentech, Inc., South San Francisco, CA, USA | |
| 700 | 1 | |a Lee, Julie |u Genentech, Inc., South San Francisco, CA, USA | |
| 700 | 1 | |a Biever, Anne |u Genentech, Inc., South San Francisco, CA, USA | |
| 700 | 1 | |a Calderon, Emilia |u Genentech, Inc., South San Francisco, CA, USA | |
| 700 | 1 | |a Teng, Edmond |u Genentech, South San Francisco, CA, USA | |
| 700 | 1 | |a Monteiro, Cecilia |u Genentech, Inc., South San Francisco, CA, USA | |
| 700 | 1 | |a Yeh, Felix L |u Genentech, Inc., South San Francisco, CA, USA | |
| 700 | 1 | |a Patania, Kaleb |u C2N Diagnostics, LLC, Saint Louis, MO, USA | |
| 700 | 1 | |a Venkatesh, Venky |u C2N Diagnostics, LLC, Saint Louis, MO, USA | |
| 700 | 1 | |a West, Tim |u C2N Diagnostics, LLC, Saint Louis, MO, USA | |
| 700 | 1 | |a Bittner, Tobias |u Genentech, Inc., South San Francisco, CA, USA | |
| 700 | 1 | |a Braunstein, Joel B. |u C2N Diagnostics, LLC, St. Louis, MO, USA | |
| 773 | 0 | |t Alzheimer's & Dementia |g vol. 21 (Dec 1, 2025) | |
| 786 | 0 | |d ProQuest |t Consumer Health Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3286011805/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3286011805/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch |